Why we don't show a single “fair value” for BYAH
A trailing-FCF DCF can't fairly anchor Park Ha Biological Technology Co., Ltd. Ordinary Shares right now — free cash flow is currently depressed by a heavy investment cycle while revenue keeps growing. For a company in this position, trailing free cash flow understates what the business actually earns for owners, so any “fair value” built on it would be misleadingly low. Off today's cash-flow base, no plausible growth rate bridges to the current price — the market is valuing normalized future cash flows, not the depressed base. The model scenarios below are shown for reference only.
| Scenario | FCF growth (fading to 2.5%) | Discount | Value / share |
|---|---|---|---|
| Conservative | 6.6%/yr | 8.5% | $18.20 |
| Base case | 9.6%/yr | 7.5% | $23.07 |
| Optimistic | 12.6%/yr | 6.5% | $30.85 |
Current Price
$2.38
Market-Implied Growth
N/A
Base-Case Model Value
$23.07
model output — not a price target
Edit the assumptions to see how they change the estimated fair value. Opens seeded with TGM's data-driven base case for BYAH (growth from its own 5-year record, discount from its beta), so the sandbox starts where the scenarios above leave off. Illustrative model — not investment advice.
Base inputs: FCF $489381 · 0.00B shares · net cash $3.7M
Estimated Fair Value
$23.07
+869.2% vs $2.38
How the estimated fair value shifts with the discount rate (WACC) and terminal growth, holding your 9.6%/yr FCF growth and 10-year horizon fixed. Green = above today's $2.38; red = below. Your current case is outlined.
| WACC ↓ / Terminal → | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
|---|---|---|---|---|---|
| 5.5% | $28.59 | $31.58 | $35.57 | $41.16 | $49.53 |
| 6.5% | $23.71 | $25.51 | $27.75 | $30.64 | $34.48 |
| 7.5% | $20.47 | $21.65 | $23.07 | $24.80 | $26.96 |
| 8.5% | $18.16 | $18.98 | $19.95 | $21.09 | $22.45 |
| 9.5% | $16.43 | $17.03 | $17.73 | $18.52 | $19.45 |
